Recently, a clinical trial phase 1b was performed in patients with advanced melanoma with a combination of anti-PD-1, anti-CTLA-4, and anti-TNFα (certolizumab and infliximab), which revealed a clinical benefit in 66.7% of the patients on certolizumab and 50% in the infliximab cohort. Here, PDCD1 is linked to melanoma.